• Journal of Applied Biological Chemistry
• /
• v.63 no.4
• /
• pp.439-442
• /
• 2020

In vitro antioxidant and anticoagulant activities of 50% ethanolic extract from Ganghwa medicinal mugwort (Artemisia princeps Pampanini) were investigated. The polyphenol and flavonoid contents of the mugwort extract were 106.9±3.3 and 34.1±0.4 mg/g-extract, respectively. The mugwort extract possessed a potent scavenging activity against radicals and nitrite, reducing power, and lipid peroxidation inhibition activity in a concentration-dependent manner. Also the mugwort extract delayed the plasma coagulation time through the inhibition of common coagulation pathway in a dose-dependent manner.

• Polymer(Korea)
• /
• v.27 no.6
• /
• pp.583-588
• /
• 2003

Sulfated chitosan and sulfated sodium alginate were synthesized by sulfating reaction of low molecular chitosan and low molecular sodium alginate with SO$_3$-pyridine complex. When the weight ratio of SO$_3$-pyridine complex to polysaccharide was 1:5, the degrees of sulfation were the highest at 2.75 and 2.53 respectively. The anticoagulation effect was the highest when the molecular weight was 8.0${\times}$10$^3$ Da, and the anticoagulation activity was the highest at 91% of that of heparin when sulfated chitosan and sulfated sodium alginate were mixed at a weight ratio of 1:1. The anticoagulation activity was highest at 84% of that of heparin in the active plastin trombo test (aPTT) when sulfated chitosan and sulfated sodium alginate were mixed at a weight ratio of 1:1.

• Journal of the Korean Society of Radiology
• /
• v.81 no.6
• /
• pp.1453-1458
• /
• 2020

Retroperitoneal hemorrhage is a potentially lethal complication in patients on anticoagulant therapy and can be caused by ovarian artery bleeding, regardless of the patients' age and obstetric history. This case illustrates the clinical presentation of ovarian artery bleeding in a postmenopausal female on anticoagulant therapy, the diagnostic utility of transcatheter angiography, and successful embolization.

• Tuberculosis and Respiratory Diseases
• /
• v.47 no.6
• /
• pp.768-774
• /
• 1999

Background: It is well known that rifampin decreases the hypoprothrombinemic effect of warfarin by induction of cytochrome P-450 enzyme in healthy volunteer. However, in patients the dosage schedule of warfarin during rifampin therapy is not established. Therefore, patients taking both rifampin and warfarin were reviewed to find out the adequate dosage schedule of warfarin in addition to side effects by interaction of two drugs. Method: Patients taking both rifampin and warfarin were retrieved from patients who were admitted due to heart disease and tuberculosis at Boochun Sejong Hospital from January of 1995 to August of 1999. To decide the adequate dosage of warfarin, the dosage of warfarin before, during, and after rifampin was evaluated in patients who kept adequate hypoprothrombinemic effect of warfarin during rifampin. To decide the adequate dosage schedule of warfarin, the time interval from the beginning of rifampin to normalization of prothrombin time(INR$\geq$1.1) was evaluated. And, the side effects by interaction of two drugs were reviewed. Results: All 12 patients taking both rifampin and warfarin were retrieved. Among them only 6 kept adequate hypoprothrombinemic effect of warfarin during rifampin. The dosage of warfarin during rifampin was $2.4{\pm}0.6$(mean$\pm$standard deviation) times as much as that before rifampin but the dosage after rifampin was the same as that before rifampin. The time interval from the beginning of rifampin to normalization of prothrombin time was $5.8{\pm}2.9$(mean${\pm}$standard deviation) days. 2 out of 12 had complication related to the interaction of rifampin and warfarin, one cerebral embolism just after the beginning of rifampin and the other cerebral hemorrhage just after the discontinuation of rifampin. Conclusion: When both rifampin and warfarin are prescribed, it would be a possible method to be confirmed by prospective study that warfarin be gradually increased about 2 times more than that without rifampin over 1 week or so after the beginning of rifampin and be tapered to the same dosage as that before rifampin when rifampin is discontinued. And, it would be prudent that prothrombin time be monitored frequently during rifampin and warfarin therapy, especially the beginning or discontinuation of rifampin.

• Journal of the Korean Arthroscopy Society
• /
• v.16 no.2
• /
• pp.121-127
• /
• 2012

Purpose: To compare coagulation test results of the arthroscopic surgery patients who received thromboprophylaxis with typical two kinds of anticoagulation drugs, we performed coagulation tests before and after surgery with two groups and then compared the results. Materials and Methods: Forty-seven patients who underwent arthroscopic surgery were randomly divided into two groups to rivaroxaban and enoxaparin group, and we performed coagulation tests before and 5 days after arthroscopic surgery to two drugs groups in order to investigate about the difference in clotting capacity. Results: Preoperative coagulation tests did not differ significantly between the two groups. However, coagulation tests after 5 days of the surgery, the level of prothrombin time-international normalized ratio (PT-INR), activated partial thromboplastin time (aPTT) increased, particularly in patients with rivaroxaban compared with enoxaparin (P<0.05). Conclusion: Anticoagulation for arthroscopic surgery with a drug is effective and has safe range in terms of bleeding tendency, but in the rivaroxaban group, there was one patient who showed high bleeding tendency with abnormal range. Therefore it should be careful of using rivaroxaban for thromboprophylaxis.

• Childhood Kidney Diseases
• /
• v.9 no.1
• /
• pp.76-82
• /
• 2005

Purpose : Regional anticoagulation with trisodium citrate for continuous renal replacement therapy(CRRT) is an effective and safe method, with lower bleeding risk. However it is not widely used because of complex current protocols used to prevent anticipated metabolic derangements. We evaluated simplified regional anticoagulation protocols with ACD-A(R) solution and commercially available calcium-containing dialysis solution. Methods : The medical records of twenty-eight patients who underwent CRRT were reviewed. Hemofilter life span according to the anticoagulation method used was compared, and laboratory findings at Pre- and 48 hours post-CRRT initiation were compared in the citrate-based CRRT group. Results : Of the twenty-eight Patients, five patients underwent citrate-based CRRT Hemofilter life span was 1.60 $\pm$ 0.72 days, showing no significant differences with the hemofilter life span in the heparin based and LMWH based CRRT group. No patients experienced hemorrhagic complications. PT, aPTT, sodium, t$CO_{2}$, iCa levels showed no difference in pre- and post-CRRT. Total calcium levels were increased. At the recommended postfilter iCa level, j.e., 0.25-0.39 mmol/L, all five patients needed increased amount of citrate infusion, and Ca infusion requirement was decreased. Conclusion : Simplified regional citrate anticoagulation with calcium-containing dialysate is an effective and safe method, and is not associated with increased hemofilter clotting. However, increased postfilter iCa level is recommended.

• Korean Journal of Food Science and Technology
• /
• v.29 no.2
• /
• pp.369-375
• /
• 1997

We have isolated an anticoagulant polysaccharide from the alkali extracts of Coriolus versicolor. The anticoagulant polysaccharide was purified through a gradual ethanol precipitation and three concecutive chromatography of DEAE-Toyopearl 650C, Sephadex G-100, and Sepharose CL-6B by measuring activated partial thromboplastin time (aPTT). The anticoagulant polysaccharide showed the homogenecity on HPLC using a gel permeation column and had about $7.2{\times}10^{5}$ molecular weight. The polysaccharide consisted of fucose, glucose, and galactose in a molar ratio of 1.0:0.2:0.2:0.1, and also compromised 19.32% of sulfate at its constituent sugars. The polysaccharide showed the two typical bands of C-O-S $(823\;cm^{-1})$ and S=O $(1257\;cm^{-1})$ in the IR spectroscopy. The sulfated polysaccharide (CV-40-Va-1) inhibited the blood coagulation via the intrinsic pathway like heparin whose activity produced a concentration dependent effect in aPTT and thrombin time (TT).

• Journal of the Korea Convergence Society
• /
• v.12 no.6
• /
• pp.249-258
• /
• 2021

The aim of this study was to determine the level of knowledge related to disease in patients with atrial fibrillation. We used the Jessa Atrial fibrillation Knowledge Questionnaire (JAKQ) and Knowledge of Atrial Fibrillation and Stroke Prevention Questionnaire(KAFSP). A total of 222 AF patients completed the JAKQ and KAFSP. The mean score of the JAKQ and KAFSP 54.7 and 18.5 points, respectively. In general, patients with Atrial fibrillation were well aware that atrial fibrillation causes stroke and that anticoagulants should be taken to prevent blood clots. However, they were not well aware of the precautions for taking anticoagulants, symptoms of atrial fibrillation, and treatment of atrial fibrillation. There was no statistically significant difference in atrial fibrillation knowledge score according to anticoagulants but the degree of knowledge related to VKA was low in patients taking VKA. The both score of JAKQ and KAFSP had significant differences in atrial fibrillation knowledge depending on the level of education. Based on these finding, it is necessary to develop a customized education program in order to improve the knowledge of patients with atrial fibrillation.

• Tuberculosis and Respiratory Diseases
• /
• v.59 no.5
• /
• pp.487-496
• /
• 2005

Background : 'Major pulmonary thromboembolism' is defined as right ventricular (RV) dysfunction, with or without shock, accompanied by significant morbidity and mortality. In this study, those with major pulmonary thromboembolism were divided into the shock and RV dysfunction only groups, and then investigated the mortality and complications in thrombolysis or anticoagulation, respectively. Methods : In a retrospective study, between January 1995 and December 2004, 60 eligible patients with a major pulmonary thromboembolism, admitted in Asan Medical Center, were included. Results : A total of 57 patients were treated with medical therapy. Thrombolysis was performed in 13 patients (23%) and anticoagulation in 44 (77%). There were no differences in the APACHEII and SOFA scores between the two groups. 6 (46%) and 11 (25%) patients died in the thrombolysis and anticoagulation groups, respectively (p=0.176). In the 19 patients (33%) showing shock, thrombolysis was performed in 9 (47%) and anticoagulation in 10 (53%). 4 (44%) of the 9 patients treated with thrombolytic agents and 3 (30%) of the 10 treated with anticoagulants died (p=0.650). In the 38 patients (67%) showing RV dysfunction only, thrombolysis was performed in 4 (11%) and anticoagulation in 34 (89%). 2 (50%) of the 4 patients treated with thrombolytics and 8 (24%) of the 34 treated with anticoagulants died (p=0.279). Three patients (23%) who underwent thrombolysis had a major bleeding episode, compared with 2 (5%) who were treated with anticoagulants (p=0.072). Conclusion: The results of our study showed that thrombolysis did not lower mortality and tended to increase major bleeding compared with anticoagulation in both the shock and RV dysfunction only groups. Further evaluation of the efficacy and safety of thrombolytic therapy for major thromboembolism appears warranted in Korea.

• Journal of Chest Surgery
• /
• v.41 no.4
• /
• pp.484-488
• /
• 2008

During long-term anticoagulation treatment with using heparin in a pregnant patient with a mechanical mitral prosthesis, we observed several anticoagulation-related complications, including repeated prosthetic valve thrombosis. This was found to be caused by heparin resistance due to an anti-thrombin III deficiency. Thrombolytic therapy using urokinase or tissue plasminogen activator (tPA) was successful and safe for her as well as her baby.